Comparative immunogenicity and neutralizing antibody responses post heterologous vaccination with CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) in HIV-infected patients with varying CD4+ T lymphocyte counts
The immune response to heterologous coronavirus disease (COVID-19) vaccination in people living with HIV (PLWH) is still unclear. Herein, our prospective cohort study aimed to compare the immune response of heterologous vaccination with CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) between PLWH ha...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2309734 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850124043830689792 |
|---|---|
| author | Sorawit Chittrakarn Pisud Siripaitoon Sarunyou Chusri Siripen Kanchanasuwan Boonsri Charoenmak Thanaporn Hortiwakul Phaiwon Kantikit Narongdet Kositpantawong |
| author_facet | Sorawit Chittrakarn Pisud Siripaitoon Sarunyou Chusri Siripen Kanchanasuwan Boonsri Charoenmak Thanaporn Hortiwakul Phaiwon Kantikit Narongdet Kositpantawong |
| author_sort | Sorawit Chittrakarn |
| collection | DOAJ |
| description | The immune response to heterologous coronavirus disease (COVID-19) vaccination in people living with HIV (PLWH) is still unclear. Herein, our prospective cohort study aimed to compare the immune response of heterologous vaccination with CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) between PLWH having CD4 counts ≤ 200 cells/µL (low CD4+) and > 200 cells/µL (high CD4+). Anti-receptor-binding domain (RBD) immunoglobulin G (IgG) levels and the percentage inhibition of neutralizing antibodies (nAbs) were analyzed at 2 and 12 weeks after immunization. Participants in the low and high CD4+ groups had mean CD4+ counts of 139 and 575 cell/µL, respectively. Two and 12 weeks after immunization, in the low CD4 group, the median anti-RBD-IgG levels were 159 IU/mL and 143 IU/mL, respectively, whereas the nAb level was 71% and decreased to 47.2%, respectively. Contrarily, the median anti-RBD-IgG levels in the high CD4+ group were 273 IU/mL and 294 IU/mL, respectively, whereas the nAb levels were 89.3% and relatively stable at 81.6%. However, although immune responses between the two study groups were not significantly different, a decline in nAb levels was observed at 12 weeks in the low CD4+ group. Therefore, a COVID-19 booster vaccine dose is suggested for immunoprotection. |
| format | Article |
| id | doaj-art-8dc17207c9db49158953c1cd14358fa5 |
| institution | OA Journals |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-8dc17207c9db49158953c1cd14358fa52025-08-20T02:34:25ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2309734Comparative immunogenicity and neutralizing antibody responses post heterologous vaccination with CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) in HIV-infected patients with varying CD4+ T lymphocyte countsSorawit Chittrakarn0Pisud Siripaitoon1Sarunyou Chusri2Siripen Kanchanasuwan3Boonsri Charoenmak4Thanaporn Hortiwakul5Phaiwon Kantikit6Narongdet Kositpantawong7Division of Infectious Disease, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, ThailandDivision of Infectious Disease, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, ThailandDivision of Infectious Disease, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, ThailandDivision of Infectious Disease, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, ThailandDivision of Infectious Disease, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, ThailandDivision of Infectious Disease, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, ThailandDepartment of Pathology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, ThailandDivision of Infectious Disease, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, ThailandThe immune response to heterologous coronavirus disease (COVID-19) vaccination in people living with HIV (PLWH) is still unclear. Herein, our prospective cohort study aimed to compare the immune response of heterologous vaccination with CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) between PLWH having CD4 counts ≤ 200 cells/µL (low CD4+) and > 200 cells/µL (high CD4+). Anti-receptor-binding domain (RBD) immunoglobulin G (IgG) levels and the percentage inhibition of neutralizing antibodies (nAbs) were analyzed at 2 and 12 weeks after immunization. Participants in the low and high CD4+ groups had mean CD4+ counts of 139 and 575 cell/µL, respectively. Two and 12 weeks after immunization, in the low CD4 group, the median anti-RBD-IgG levels were 159 IU/mL and 143 IU/mL, respectively, whereas the nAb level was 71% and decreased to 47.2%, respectively. Contrarily, the median anti-RBD-IgG levels in the high CD4+ group were 273 IU/mL and 294 IU/mL, respectively, whereas the nAb levels were 89.3% and relatively stable at 81.6%. However, although immune responses between the two study groups were not significantly different, a decline in nAb levels was observed at 12 weeks in the low CD4+ group. Therefore, a COVID-19 booster vaccine dose is suggested for immunoprotection.https://www.tandfonline.com/doi/10.1080/21645515.2024.2309734COVID-19people living with HIVSARS-CoV-2 vaccineanti-receptor-binding domain immunoglobulin Gneutralizing antibodies |
| spellingShingle | Sorawit Chittrakarn Pisud Siripaitoon Sarunyou Chusri Siripen Kanchanasuwan Boonsri Charoenmak Thanaporn Hortiwakul Phaiwon Kantikit Narongdet Kositpantawong Comparative immunogenicity and neutralizing antibody responses post heterologous vaccination with CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) in HIV-infected patients with varying CD4+ T lymphocyte counts Human Vaccines & Immunotherapeutics COVID-19 people living with HIV SARS-CoV-2 vaccine anti-receptor-binding domain immunoglobulin G neutralizing antibodies |
| title | Comparative immunogenicity and neutralizing antibody responses post heterologous vaccination with CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) in HIV-infected patients with varying CD4+ T lymphocyte counts |
| title_full | Comparative immunogenicity and neutralizing antibody responses post heterologous vaccination with CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) in HIV-infected patients with varying CD4+ T lymphocyte counts |
| title_fullStr | Comparative immunogenicity and neutralizing antibody responses post heterologous vaccination with CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) in HIV-infected patients with varying CD4+ T lymphocyte counts |
| title_full_unstemmed | Comparative immunogenicity and neutralizing antibody responses post heterologous vaccination with CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) in HIV-infected patients with varying CD4+ T lymphocyte counts |
| title_short | Comparative immunogenicity and neutralizing antibody responses post heterologous vaccination with CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) in HIV-infected patients with varying CD4+ T lymphocyte counts |
| title_sort | comparative immunogenicity and neutralizing antibody responses post heterologous vaccination with coronavac sinovac and vaxzevria astrazeneca in hiv infected patients with varying cd4 t lymphocyte counts |
| topic | COVID-19 people living with HIV SARS-CoV-2 vaccine anti-receptor-binding domain immunoglobulin G neutralizing antibodies |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2309734 |
| work_keys_str_mv | AT sorawitchittrakarn comparativeimmunogenicityandneutralizingantibodyresponsespostheterologousvaccinationwithcoronavacsinovacandvaxzevriaastrazenecainhivinfectedpatientswithvaryingcd4tlymphocytecounts AT pisudsiripaitoon comparativeimmunogenicityandneutralizingantibodyresponsespostheterologousvaccinationwithcoronavacsinovacandvaxzevriaastrazenecainhivinfectedpatientswithvaryingcd4tlymphocytecounts AT sarunyouchusri comparativeimmunogenicityandneutralizingantibodyresponsespostheterologousvaccinationwithcoronavacsinovacandvaxzevriaastrazenecainhivinfectedpatientswithvaryingcd4tlymphocytecounts AT siripenkanchanasuwan comparativeimmunogenicityandneutralizingantibodyresponsespostheterologousvaccinationwithcoronavacsinovacandvaxzevriaastrazenecainhivinfectedpatientswithvaryingcd4tlymphocytecounts AT boonsricharoenmak comparativeimmunogenicityandneutralizingantibodyresponsespostheterologousvaccinationwithcoronavacsinovacandvaxzevriaastrazenecainhivinfectedpatientswithvaryingcd4tlymphocytecounts AT thanapornhortiwakul comparativeimmunogenicityandneutralizingantibodyresponsespostheterologousvaccinationwithcoronavacsinovacandvaxzevriaastrazenecainhivinfectedpatientswithvaryingcd4tlymphocytecounts AT phaiwonkantikit comparativeimmunogenicityandneutralizingantibodyresponsespostheterologousvaccinationwithcoronavacsinovacandvaxzevriaastrazenecainhivinfectedpatientswithvaryingcd4tlymphocytecounts AT narongdetkositpantawong comparativeimmunogenicityandneutralizingantibodyresponsespostheterologousvaccinationwithcoronavacsinovacandvaxzevriaastrazenecainhivinfectedpatientswithvaryingcd4tlymphocytecounts |